Division of Kubota Pharmaceutical Holdings Co. Ltd.
Latest From Acucela Inc.
French biotech Horama has built-up its executive team and has two potential gene therapies for retinitis pigmentosa nearing the clinic.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.
While reimbursement pricing issues and policies dominated the Japanese pharma market in 2016, there was also notable commercial activity during the year, although this was more about refocusing and reducing rather than major mergers and acquisitions.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Kubota Pharmaceutical Holdings Co. Ltd.
- Senior Management
Ryo Kubota, MD, PhD, Chmn., Pres. & CEO
John Gebhart, CFO
Ted Danse, CBO
Lukas Scheibler, PhD, EVP, R&D
- Contact Info
Phone: (206) 805-8300
1301 Second Ave., Ste. 4200
Seattle, WA 98101-3805
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.